MedTrace Logo

Left Atrial Appendage Occlusion Versus New Oral Anticoagulants for Stroke Prevention in Patients With Non-valvular Atrial Fibrillation

NCT03108872 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2017-05-24

No results posted yet for this study

Summary

We will compare long-term effectiveness and safety in patients with atrial fibrillation treated with left atrial appendage occlusion versus new oral anticoagulants to prevent ischemic stroke from multicenter registry data

Conditions

Interventions

DEVICE

left atrial appendage occlusion

Percutaneous exclusion of left atrial appendage with Watchman or ACP devices

DRUG

New oral anticoagulants

Include dabigatran, rivaroxaban, apixaban and edoxaban

Sponsors & Collaborators

  • Korea University Anam Hospital

    collaborator OTHER

  • Yonsei University

    collaborator OTHER

  • Gachon University Gil Medical Center

    collaborator OTHER

  • Ulsan University Hospital

    collaborator OTHER

  • Sejong General Hospital

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-23
Primary Completion
2017-09-30
Completion
2017-10-30
FDA Device
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03108872 on ClinicalTrials.gov